Buijk S E, Mouton J W, Gyssens I C, Verbrugh H A, Bruining H A
Dept. of Surgical Intensive Care, Erasmus MC Rotterdam, P.O. Box 2040, 3000 CA Rotterdam, The Netherlands.
Intensive Care Med. 2002 Jul;28(7):936-42. doi: 10.1007/s00134-002-1313-7. Epub 2002 May 30.
As aminoglycosides show concentration-dependent killing, once-daily aminoglycoside (ODA) regimens have been instituted. Data on experience with ODA regimens in critically ill patients are limited.
A prospective, descriptive study.
Eighteen-bed surgical and 12-bed medical intensive care unit in a referral centre.
Eighty-nine critically ill patients with a suspected or confirmed infection for which gentamicin or tobramycin was indicated and a creatinine clearance > 30 ml/min were monitored. One hundred and nine pharmacokinetic profiles were gathered.
A first dose of 7 mg/kg/24 h of gentamicin or tobramycin was given to every patient independent of renal function. Subsequent doses were chosen on the basis of the pharmacokinetic results of the first dose.
Serum samples were collected 1 h and 6 h after start of the aminoglycoside infusion. All samples were assayed by using immunofluorescence. Pharmacokinetic parameters were estimated using a one-compartment model.
The volume of distribution of aminoglycosides was significantly higher in critical ill patients with septic shock than in those without. Consequently, the maximum concentration reached was significantly lower in patients with septic shock. In P. aeruginosa infections the mean (SD) estimated Cmax/MIC ratio was 10.3 (3.3). In n = 17 (49%) of the patients treated > 24 h ( n = 35), a dose adjustment or lengthening of interval was necessary. The recommended dosing interval based on the Hartford Hospital nomogram and one-serum concentration at 6 h was correct in only 62% of all cases. Signs of renal impairment occurred in n = 12 (14%) of the patients; in all survivors renal function recovered completely and no haemofiltration was needed.
An ODA-regimen of 7 mg/kg produced Cmax/MIC ratios > 10 in the majority of critically ill patients in our population. Septic shock and renal dysfunction caused an aberrant pharmacokinetic profile of aminoglycosides in these patients. Therefore, individual therapeutic drug monitoring is warranted. Signs of renal impairment were common in the presence of shock, but appeared to be reversible.
由于氨基糖苷类药物具有浓度依赖性杀菌作用,因此已采用每日一次氨基糖苷类(ODA)给药方案。关于ODA方案在重症患者中的应用经验数据有限。
1)评估重症患者的ODA方案;2)描述氨基糖苷类药物(庆大霉素和妥布霉素)的药代动力学;3)评估该特定患者群体中与ODA方案相关的肾毒性发生率。
一项前瞻性描述性研究。
一家转诊中心的拥有18张床位的外科重症监护病房和拥有12张床位的内科重症监护病房。
对89例疑似或确诊感染且肌酐清除率>30 ml/min、需要使用庆大霉素或妥布霉素的重症患者进行监测。共收集了109份药代动力学资料。
不论肾功能如何,每位患者均给予首剂7 mg/kg/24 h的庆大霉素或妥布霉素。后续剂量根据首剂药代动力学结果选择。
在氨基糖苷类药物输注开始后1小时和6小时采集血清样本。所有样本均采用免疫荧光法检测。药代动力学参数采用一室模型估算。
感染性休克的重症患者中氨基糖苷类药物的分布容积显著高于未发生感染性休克的患者。因此,感染性休克患者达到的最高浓度显著较低。在铜绿假单胞菌感染中,平均(标准差)估算的Cmax/MIC比值为10.3(3.3)。在接受治疗>24小时(n = 35)的患者中,有n = 17例(49%)需要调整剂量或延长给药间隔。根据哈特福德医院列线图和6小时时的单次血清浓度推荐的给药间隔在所有病例中仅62%是正确的。12例(14%)患者出现肾功能损害迹象;所有存活患者的肾功能均完全恢复,无需进行血液滤过。
在我们的研究人群中,大多数重症患者采用7 mg/kg的ODA方案可使Cmax/MIC比值>10。感染性休克和肾功能不全导致这些患者的氨基糖苷类药物药代动力学特征异常。因此,有必要进行个体化治疗药物监测。在休克状态下肾功能损害迹象常见,但似乎是可逆的。